Analgosedation: A paradigm shift in intensive care unit sedation practice;Sedación Mediante Analgésicos: Un Cambio en Paradigma en la Sedación de Cuidado Intensivo

Annals of Pharmacotherapy

Volumn 46, Issue 4, 2012, Pages 530-540

  Devabhakthuni, Sandeep ^a,b   Armahizer, Michael J ^a   Dasta, Joseph F ^c,d   Kane Gill, Sandra L ^e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Analgosedation; Remifentanil

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DEXMEDETOMIDINE; FENTANYL; LORAZEPAM; MIDAZOLAM; MORPHINE; PROPOFOL; REMIFENTANIL;

ANALGOSEDATION; ARTIFICIAL VENTILATION; ASYSTOLE; BRADYCARDIA; CHEST WALL RIGIDITY; CLINICAL PRACTICE; CLINICAL STUDY; COCHRANE LIBRARY; CRITICALLY ILL PATIENT; DELIRIUM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; GASTRIC DYSMOTILITY; HALLUCINATION; HEART ARRHYTHMIA; HEMODYNAMICS; HUMAN; HYPERALGESIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IMMUNE DEFICIENCY; INFORMATION RETRIEVAL; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; LENGTH OF STAY; MEDLINE; METABOLIC ACIDOSIS; NIGHTMARE; PANCREATITIS; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATION DEPRESSION; REVIEW; RHABDOMYOPATHY; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; VITAL SIGN; WITHDRAWAL SYNDROME;

ANALGESIA; ANALGESICS; CRITICAL ILLNESS; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE UNITS; LENGTH OF STAY; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME;

EID: 84859707414     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q525     Document Type: Review

References (75)

1. Soliman HM, Mélot M, Vincent JL. Sedative and analgesic practice in the intensive care unit: the results of a European survey. Br J Anaesth 2001;87:186-92.
2. Tonner PH, Weiler N, Paris A, Scholz J. Sedation and analgesia in the intensive care unit. Curr Opin Anaesthesiol 2003;16:113-21.
3. Rhoney DH, Murry KR. National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med 2003;18:139-45.
4. Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995;346:145-7.
5. Nelsen JL, Haas CE, Habtemariam B, et al. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med 2008;23:184-94.
6. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-7.
7. Gïlinas C. Management of pain in cardiac surgery ICU patients: have we improved over time? Intensive Crit Care Nurse 2007;23:298-303.
8. Ethier C, Burry L, Martinez-Motta C, et al. Recall of intensive care unit stay in patients managed with a sedation protocol or a sedation protocol with daily sedative interruption: a pilot study. J Crit Care 2011;26:127-32.
9. Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and opioids analgesics on the development of delirium following hip fracture. J Gerontol 2003;58A:76-81.
10. Mattia C, Savoia G, Paoletti F, et al. SIAARTI recommendations for analgo-sedation in intensive care unit. Minerva Anestesiol 2006;72:769-805.
11. Sessler CN, Varney K. Patient-focused sedation and analgesia in the ICU. Chest 2008;133:552-65.
12. Egerod I. Cultural changes in ICU sedation management. Qual Health Res 2009;19:687-96.
13. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnoticbased regimens in intensive care unit patients with brain injuries: a randomized, controlled trial. Crit Care 2004;8:R268-80. DOI 101186/cc2896
14. Park G, Lane M, Rogers S, Bassett P. A comparison of hypnotic and analgesic based sedation in a general intensive care unit. Br J Anaesth 2007;98:76-82.
15. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41.
16. Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999;27:2609-15.
17. Marshall J, Finn CA, Theodore AC. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay. Crit Care Med 2008;36:626-8.
18. Chanques G, Jaber S, Barbotte E, et al. Impact of a systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med 2006;24: 1691-9.
19. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomized controlled trial. Lancet 2008;371:126-34.
20. Tanios MA, de Wit M, Epstein SK, Devlin JW. Perceived barriers to the use of sedation protocols and daily sedation interruption: a multidisciplinary survey. J Crit Care 2009;24:66-73.
21. Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med 2006; 34:374-80.
22. Jackson DL, Proudfoot CW, Cann KF, Walsh T. A systematic review of the impact of sedation practice in the ICU on resource use, costs and patient safety. Crit Care 2010;14:R59. DOI 10.1186/cc8956
23. Jackson DL, Proudfoot CW, Cann KF, Walsh T. The incidence of suboptimal sedation in the ICU: a systematic review. Crit Care 2009;13:R204. DOI 10.1186/cc8212
24. Payen JF, Chanques G, Mantz J, et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a prospective multicenter patient-based study. Anesthesiology 2007;106:687-95.
25. Dasta JF, Kane-Gill S. Pharmacoeconomics of sedation in the ICU. Crit Care Clin 2009;25:571-83.
26. Nseir S, Makris D, Mathieu D, Durocher A, Marquette CH. Intensive care unit-acquired infection as a side effect of sedation. Crit Care 2010;14:R30. DOI 10.1186/cc8907
27. Peck M, Down J. Use of sedatives in the critically ill. Anaesth Intensive Care 2010;11:12-5.
28. Weinert CR, Calvin AD. Epidemiology of sedation and sedation adequacy for mechanically ventilated patients in a medical and surgical intensive care unit. Crit Care Med 2007;35:393-401.
29. Szumita PM, Baroletti SA, Anger KE, Wechsler ME. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm 2007;64:37-44.
30. American Pain Society. Principles of analgesic use in the treatment of acute pain and chronic cancer pain. 5th ed. Glenview, IL: American Pain Society, 2003.
31. Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo AS, Parker KL, eds. The pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006:547-90.
32. Greenblatt DJ, Divoll M, Abernathy DR, Ochs HR, Shader RI. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1983;8:233-52.
33. Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des 2004;10:3639-49.
34. Gesin G, Dasta J, Kane-Gill S, Birer K, Cheatham M. Goal-directed sedation of critically ill trauma patients using diazepam as a component of therapy. J Crit Care 2011;26:122-6.
35. Ingersoll-Weng E, Manecke GR, Thistlethwaite PA. Dexmedetomidine and cardiac arrest. Anesthesiology 2004;100:738-9.
36. Martin E, Ramsay G, Mantz J et al. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med 2003;18:29-41.
37. Wilson KC, Reardon C, Theodore AC, Farber HW. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest 2005;128:1674-81.
38. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006;104:21-6.
39. Amrein R, Hetzel W, Bonetti EP, Gerecke M. Clinical pharmacology of Dormicum (midazolam) and Anexate (flumazenil). Resuscitation 1988;16:S5-27.
40. Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003;29:1417-25.
41. Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia 2007;62:690-701.
42. Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy 2005;25:1348-52.
43. Kumar AN, Schwartz DE, Lim KG. Propofol-induced pancreatitis: recurrence of pancreatitis after rechallenge. Chest 1999;115:1198-9.
44. Muzi M, Berens RA, Kampine JP, Ebert TJ. Venodilation contributes to propofol-mediated hypotension in humans. Anesth Analg 1992;74:877-83.
45. Bilotta F, Fiorani L, Rosa IL, Spinelli F, Rosa G. Cardiovascular effects of intravenous propofol administered at two infusion rates: a transthoracic echocardiographic study. Anaesthesia 2001;56:266-71.
46. Sebel PS, Lowdon J. Propofol: a new intravenous anesthetic. Anesthesiology 1989;71:260-77.
47. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs. lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007;298:2644-53.
48. Shehabi Y, Riker RR, Bokesch PM, Wisemandle W, Shintani A, Ely EW. Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients. Crit Care Med 2010;38:2311-8.
49. Corbett SM, Montoya ID, Moore FA. Propofol-related infusion syndrome in intensive care patients. Pharmacotherapy 2008;28:250-8.
50. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009;301:489-99.
51. Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine Compared to Morphine-DEXCOM Study). Anesthesiology 2009;111:1075-84.
52. Devabhakthuni S, Pajoumand M, Williams C, Kufera JA, Watson K, Stein DM. Evaluation of dexmedetomidine: safety and clinical outcomes in critically ill trauma patients. J Trauma 2011;71:1164-71. DOI 10.1097/TA.0b013e3182147670
53. Wilhelm W, Kreuer S. The place for short-acting opioids: special emphasis on remifentanil. Critical Care 2008;12:S5. DOI 10.1186/cc6152
54. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996;12:182-9.
55. Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: a study of risk factors. Intensive Care Med 2001;27:1297-304.
56. Nseir S, Hoel J, Grailles G, et al. Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study. Crit Care 2009;13:R60. DOI 10.1186/cc7788
57. Pitslu M, Wilmer A, Bodenham A, et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth 2004;92:493-503.
58. Breen D, Wilmer A, Bodenham A, et al. Offset of pharmacodynamics effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Crit Care 2004;8:R21-30. DOI 10.1186/cc2399
59. Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993;79:893-903.
60. Glass PS. Pharmacology of remifentanil. Eur J Anesthesiol 1995;10(suppl): 73-4.
61. Egan TD, Lemmens HJ, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI7084B) in healthy adult male volunteers. Anesthesiology 1993;79:881-92.
62. Chinachoti T, Kessler P, Kirkham A, Werawatganon T. Remifentanil vs. morphine for patients in intensive care unit who need short-term mechanical ventilation. J Med Assoc Thai 2002;85:S848-57.
63. Dahaba AA, Grabner T, Rehak PH, List WF, Metzler H. Remifentanil versus morphine analgesia and sedation for mechanically ventilated critically ill patients: a randomized double blind study. Anesthesiology 2004;101:640-6.
64. Muellejans B, López A, Cross MH, Bonome C, Morrison L, Kirkham AJ. Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial. Critical Care 2004;8:R1-11. DOI 10.1186/cc2398
65. Rauf K, Vohra A, Fernandez-Jimenez P, O'Keeffe N, Forrest M. Remifentanil infusion in association with fentanyl-propofol anaesthesia in patients undergoing cardiac surgery: effects on morphine requirement and postoperative analgesia. Br J Anaesth 2005;95:611-5.
66. Carrer S, Brocchi A, Candini M, et al. Short term analgesia based sedation in the intensive care unit: morphine vs. remifentanil + morphine. Minerva Anestesiologica 2007;73:327-32.
67. Breen D, Karabinis A, Malbrain M, et al. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomized trial. Critical Care 2005;9:R200-10. DOI 10.1186/cc3495
68. Muellejans B, Matthey T, Scholpp J, Schill M. Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomized, open-label, pharmacoeconomic trial. Critical Care 2006;10: R91. DOI 10.1186/cc4939
69. Rozendaal FW, Spronk PE, Snellen FF, et al. Remifentanil-propofol analgo-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, openlabel study in the Netherlands. Intensive Care Med 2009;35:291-8.
70. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomized trial. Lancet 2010;375:475-80.
71. Al MJ, Hakkaart L, Tan SS, Bakker J. Cost-consequence analysis of remifentanil-based analgosedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. Crit Care 2010;14:R195. DOI 10.1186/cc8616
72. Rundshagen I, Schnabel K, Wegner C, Sculte AM Esch J. Incidence of recall, nightmares, and hallucinations during analgosedation in intensive care. Intensive Care Med 2002;28:38-43.
73. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003;106:49-57.
74. Dasta JF, Kane-Gill SL, Pencina M, et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. Crit Care Med 2010;38:497-503.
75. Memis D, Inal MT, Kavalci G, Sezer A, Sut N. Intravenous paracetamol reduced the use of opioids, extubation time, and opioid-related adverse effects after major surgery in intensive care unit. J Crit Care 2010;25: 458-62.